BZ371B / Biozeus, Claritas Pharma - LARVOL DELTA

Efficacy and Safety Evaluation of BZ371B in ARDS Patients (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Biozeus Biopharmaceutical S.A. | N=10 ➔ 1 | Trial completion date: Nov 2023 ➔ Mar 2023 | Not yet recruiting ➔ Terminated | Trial primary completion date: Nov 2022 ➔ Mar 2023; Suboptimal enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Respiratory Distress Syndrome • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety Evaluation of BZ371B in ARDS Patients (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Biozeus Biopharmaceutical S.A. | Trial completion date: Jun 2023 ➔ Nov 2023 | Initiation date: Jun 2022 ➔ Nov 2022 | Trial primary completion date: Jun 2022 ➔ Nov 2022

Trial completion date • Trial initiation date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety Evaluation of BZ371B in ARDS Patients (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Biozeus Biopharmaceutical S.A.

New P1 trial • Acute Respiratory Distress Syndrome • Infectious Disease • Pulmonary Disease • Respiratory Diseases